The Academy of Pharmaceutical Sciences
'Promoting the pharmaceutical sciences'

Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets.....           Study: Roche's cheaper Avastin just as safe as Lucentis in eye disease.....           Balky payers, beware: Gilead eyes $95K-or-so price for Sovaldi combo pill.....           Salix hands off Relistor, other drugs to Lupin in Canada.....           Would Ian Read keep his AZ deal promises? U.K. panel eyes new rules to enforce them.....           Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics.....           Lakewood-Amedex gets notice of allowance from USPTO for new patent covering nanoRNA gene-silencing technology.....           Grafix randomized controlled clinical trial recognized as high quality DFU trial in recent wounds supplement.....           Marina Biotech announces continued worldwide expansion of Delivery Technology Intellectual Property Estate.....           Prosonix confirms potential of MCP Technology to develop new FDC therapies for respiratory diseases.....           NeoStem enters into license deal with Rockefeller University to expand cancer immunotherapy.....           FDA approves Takeda and Orexigen's Contrave for chronic weight management.....           Cellerant gets $47.5m contract to support development of CLT-008.....           Lilly says with new data, it will seek another approval for Cyramza next year.....           Novo and Orexigen obesity drugs are coming, but will consumers embrace them?.....           With inversion pushback mounting, Akorn eyes bid for UCB subsidiary.....           Amarin loses a second FDA appeal over omega-3 pill Vascepa.....           J&J trims pension benefits for new hires.....           As America's diabetes problem grows, so do prices on Lilly's Humulin.....           Lilly says with new data, it will seek second approval for Cyramza next year.....           Asterias, Cancer Research UK ink deal for new lung cancer vaccine.....           Genocea begins Phase IIa trial of GEN-004 to treat pneumococcus.....           FDA grants orphan drug status for Viamet's VT-1129 to treat cryptococcal meningitis.....           Abbvie reports positive Phase III trial results of Humira in hidradenitis suppurativa patients.....           Oxygen Biotherapeutics halts Phase IIb traumatic brain injury trial of Oxycyte.....           Cantrell improves compounding safety with closed vial filling system from Aseptic Technologies.....           New medicines in development give hope to patients with HIV/AIDS.....           EMD Serono, Accelerated Cure Project to optimize treatment and understand progression of multiple sclerosis.....           FDA approves Astellas and Medivation's expanded use of prostate cancer drug Xtandi.....           Oculus launches OTC advanced scar management hydrogel in US.....           G1 Therapeutics begins Phase I clinical trial of G1T28-1 for several oncology indications.....           Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets.....           Takeda preps to launch Orexigen's obesity drug Contrave as Novo's Saxenda looms.....           Meet Baxalta, the pharma spinoff Baxter plans to unleash in 2015.....           Pre-chemo nod for Medivation's Xtandi sets up showdown with J&J's Zytiga.....           Allergan special meeting could happen with or without Ackman's stake.....           The huge price hike as sales strategy, taken to extremes by Retrophin.....           Lilly and Boehringer's insulin glargine product gets European marketing approval.....           ViaCyte gets $16.6m grant from CIRM to develop VC-01 diabetes therapy candidate.....           Mylan Ireland to buy US rights of Arixtra injection from Aspen.....           GSK joins with research councils in UK and South Africa to tackle non-communicable diseases in Africa.....           Seattle Genetics enters into antibody-drug conjugate deal with Genmab.....           Teva Canada launches Escitalopram generic version of Cipralex.....           Soligenix announces issuance of US Patent for ThermoVax Technology.....           C3 Jian completes Phase II clinical trial of anti-cavity drug.....           OnCore, NeuroVive partner for second-generation cyclophilin inhibitors to treat HBV.....           Evoke Pharma completes patient enrollment in ECG trial for EVK-001.....           Lee's Pharmaceutical ink deal with Abiogen to market cholecalciferol.....           USPTO issues three additional patents to strengthen Mersana's ADC technologies.....           Sutro Biopharma to collaborate with University of California as part of Recombinant Antibody Network.....           Relypsa announces commercial manufacturing agreement with Patheon.....           NICE to bypass drugmakers in search of data to support pricey drugs.....           Merck's Frazier disses tax inversion strategy, at least for Merck.....           With $1M gene therapies coming, research pioneer and CVS plot new payment route.....           Wake up, Ackman tells Allergan's board. He has a 50%-60% chance of replacing you.....           Mylan challenges Big Pharma's clot fighters with $300M Arixtra buy.....           Big Pharma's patent cliff losses spawn $239B savings on 2013 drug spending.....           Free speech, PhRMA? Not in this off-label marketing case, feds say.....           SRI International, Nobelpharma ink deal to develop endometriosis drug.....           Galena doses first patient in Phase II trial of GALE-401 to treat MPN-related thrombocytosis.....           Ebola outbreak 'serious threat' to Liberia's national existence, says defence minister.....           Alternaturals announces exclusive new products and marketing strategy.....           SRI International, Nobelpharma ink deal to develop endometriosis drug.....           Roche's RoACTEMRA gets European approval to treat early rheumatoid arthritis.....           PharmAthene, Nanotherapeutics to advance biodefense programs.....           Momenta exercises option to buy new antibody program from AnaptysBio.....           Critical Outcome Technologies, UT MD Anderson sign letter of ontent for Phase 1 development of COTI-2.....           Roche's RoACTEMRA gets European approval to treat early rheumatoid arthritis.....           Emergent BioSolutions to develop dry formulation of anthrax vaccine NuThrax.....           Pfizer Japan, Astellas to terminate distribution and co-promotion of Caduet combination tablets.....           The top 10 best-selling multiple sclerosis drugs of 2013.....           NICE says 'too pricey' to Celgene's Abraxane combo for pancreatic cancer.....           Feds eyed GlaxoSmithKline's Chinese consumer biz for bribery, too.....           Judge: Merck must fight claims that it lied about mumps vaccine benefits.....           Teva CFO: We're looking to grow sales, not slash and burn costs.....           The pressure's on Novo's marketing force as FDA nod for liraglutide nears.....           GlaxoSmithKline's Phase IIIb/IV combination trial for hypertension meets primary endpoint.....           UK plans new medical centre in Sierra Leone to treat Ebola virus victims.....           University of Toronto, Janssen to research new treatments for major brain disorders.....           Molecular Templates' IND application for MT-3724 gets FDA clearance.....           Par Pharmaceutical resumes shipment of generic Precedex injection.....           Pharmatech enters into research collaboration with Weill Cornell Medical College.....           FDA accepts filing of Astellas' NDA for isavuconazole to treat fungal infections.....           Mylan introduces generic Boniva injection.....           Breckenridge announces paragraph IV ANDA litigation with Novartis for generic version of Zortress.....           ACT gets US patent for dendritic cells manufacturing from renewable stem cell sources.....           FDA faces pressure to green-light generic versions of AZ's pricey Nexium.....           Bristol-Myers socks Merck's brand-new Keytruda with PD-1 patent suit.....           Latest Allergan buzz puts Ireland's Jazz in its dealmaking sights.....           Sales layoffs may be ahead as Hospira loses fight against Precedex generics.....           U.K. watchdogs hope to tap social media for drug-safety purposes.....           Europe opens up big new market for Roche's RA therapy RoActemra.....           FTC takes after AbbVie, Teva for pay-for-delay deal on AndroGel.....           Takeda submits NDA for Leuplin to treat hormone-dependent diseases in Japan.....           WellSpring acquires motion sickness drug BONINE from Prestige Brands.....           FDA accepts Actavis' NDA filing for ceftazidime-avibactam.....           Soligenix expands pipeline with acquisition of Phase III-ready oncology clinical program.....           Melinta reports PK profile of single oral dose delafloxacin to support US Phase III gonorrhea program.....           Meiji, Takeda enter into co-promotion agreement for insomnia drug Rozerem in Japan.....           RSS NEWSFEED....
Welcome to
The Academy of
Pharmaceutical Sciences
The Academy of Pharmaceutical Sciences is the professional body for the Pharmaceutical Sciences in United Kingdom. A Pharmaceutical Scientist is an individual who contributes to bringing a new drug from concept through to a medicinal product. This includes, but is not exclusive to, individuals in academia, industry, regulation, clinical research and manufacturing.

The mission of the Academy of Pharmaceutical Sciences is to champion innovation and opportunity in Pharmaceutical Sciences for the delivery of medicines.

In order to achieve this mission, our aims are to:

  • Promote the Pharmaceutical Sciences to stakeholders to facilitate understanding and achieve engagement
  • Share learning, drive collaboration, partnership and innovation
  • Deliver insights into industry and academic roles for aspiring scientists
Latest News
Unique leadership event for women in healthcare science leadership
The Academy of Pharmaceutical Sciences (APS) and Royal Pharmaceutical Society (RPS) are organising a symposium on the 7 October 2014 for women in healthcare science leadership.. The organisers have put together a panel of leading professionals to help women develop their careers and includes eminent speakers from across clinical pharmacy, academic research and industry. The event is attracting a wide audience of individuals involved in leadership in the healthcare science and we would love to see you there.. . Are you looking to take the next step in your career? Are you ready to set new challenges and enhance your leadership skills?. Join us to hear from inspiring leaders in academic research, clinical pharmacy, and industry.. Helen Gordon, Chief Executive, Royal Pharmaceutical Society, says: “Our Women in healthcare science leadership symposium is a new event, developed to support women in existing or aspiring leadership roles. Attending will provide you with the perfect opportunity to challenge what you know about yourself and develop practical skills that will support your career. I for one am looking forward to hearing from our great line-up of speakers, who I’m sure will inspire and motivate you to excel and lead others in your field.”. The symposium has great networking potential with speakers from across clinical pharmacy, academic research and life sciences including:. Cathy Mooney MRPharmS, Deputy Director of Quality and Safety, University College London Hospitals NHS Foundation Trust Harriet Fear, CEO, One Nucleus Helena Morrissey CBE, CEO, Newton and Founder 30% Club Philippa Roberts MRPharmS, Director of Pharmacy and Risk Management, Wirral University Teaching Hospital NHS Foundation Trust Themes include leadership, innovation and entrepreneurship. During the day, you will:. Learn how to develop your leadership skills and successfully drive your career forwards Identify the successes and challenges for women in the workplace Discuss real life experiences with leading healthcare practitioners Examine the benefits of diversity in the workplace Learn how to overcome the barriers (both real and perceived) to becoming a leader Learn how to influence at the most senior level and to build networks. There will also be a Q&A session, giving you the unique opportunity to ask specific questions relating to your career.. We aim to provide you with the skills and confidence to successfully drive your career forward. Don't miss out: view the full programme and register today..,2SN4Q,G415KU,A5V2J,1.
Award Winners at APS PharmSci 2014
APS Invited lecture at PharmSci Conference 2014 on Monday September 8th from 13.45-14.35. . The APS are pleased to announce that Abdul Basit will deliver the APS lecture this year entitled Gut instincts: explorations in intestinal physiology and drug delivery. The APS lecture award is sponsored by AstraZeneca and is awarded to nominated members of APS who have made outstanding scientific contribution in their work and are ambassadors in their area with an international reputation.. Abdul Basit holds the position of Professor of Pharmaceutics at the University College London (UCL) School of Pharmacy. He is also a Visiting Professor in the Faculty of Chemical and Pharmaceutical Sciences at the University of Chile. Furthermore, he holds an Honorary Research Fellow in Gastroenterology at the Wingate Institute of Neurogastroenterology, Queen Mary College, University of London.. Abdul's research sits at the interface between pharmaceutical science and gastroenterology, forging links between basic science and clinical outcomes. He leads a large and multi-disciplinary research group, and the goal of his work is to further the understanding of gastrointestinal physiology by fundamental research. So far, this knowledge has been translated into the design of new technologies and improved disease treatments, many of which are currently in late stage clinical trials.. Abdul is also the only non-North American scientist to receive the Young Investigator Award in Pharmaceutics and Pharmaceutical Technology from the American Association of Pharmaceutical Scientists (AAPS). Moreover, he is the founder and director of two spin-out companies, and serves on the scientific advisory boards of pharmaceutical companies, healthcare organisations and charitable bodies, including the Clinton Health Access Initiative (CHAI).. . Winner of the 2014 Royal Pharmaceutical Society Science Award announced. Professor Benjamin J. Whalley has been announced as winner of the 2014 Royal Pharmaceutical Society’s prestigious Science Award. The award will be presented at the APS PhamSci 2014 conference at the University of Hertfordshire, when Professor Whalley will deliver a plenary lecture on The therapeutic value of non-psychoactive components of cannabis in epilepsy: from lab to clinic.. The lecture will take place on Tuesday 9th September at 1335.. . . . The RPS Science Award has a long history with previous winners invariably going on to make significant contributions in the field of pharmaceutical science. The award is presented to a pharmaceutical scientist with no more than 10 years’ experience at post-doctoral level who has a proven record of independent research and published work that shows outstanding promise.. Professor Benjamin J. Whalley studies neuronal processes that underlie complex physiological functions, specifically neuronal hyperexcitability states and their consequential disorders (e.g. epilepsy, ataxia and dystonias). As a registered pharmacist (1992-present), Professor Whalley’s research in this area has primarily focused upon preclinical drug development in epilepsy. Here, he has primarily employed electrophysiological approaches with a variety of in vitro models of epileptiform activity and a number of in vivo rodent models of seizure and epilepsy.. He has used these approaches to examine the cellular and neuronal network mechanisms that underlie the effects of anti-epileptic drugs (AEDs) that are in clinical use or currently in clinical trials (e.g. levetiracetam (UCB Pharmaceuticals), carisbamate and topiramate (RW Johnson)). More recently, his work has examined the effects of several non-psychoactive components of marijuana (‘phytocannabinoids’) upon hyperexcitability states. Here, he has demonstrated that several of these phytocannabinoids exert significant anti-epileptic effects and, since 2008, has worked with GW Pharmaceuticals and Otsuka Pharmaceuticals to develop these drugs to the point of translation to human clinical trials. This work has yielded 4 international patents and, in 2013, initiation of Phase 1 human clinical trials for one drug (cannabidavarin) and Phase 2 human clinical trials for another (cannabidiol) in drug resistant, pediatric epilepsies. Early efficacy data from these trials has shown that cannabidiol has beneficial effects upon seizures in otherwise treatment-resistant paediatric epilepsy patients.. Prof. Whalley’s expertise in this area is further reflected in his role as an expert witness in criminal trials involving cannabis, his invited authorship of The American Herbal Pharmacopeia’s monograph on Cannabis and Epilepsy and recent appointment to the UK Advisory Council on the Misuse of Drugs. His work with non-psychoactive phytocannabinoids has also included work with colleagues which has revealed cannabinoid effects upon appetite and feeding behaviours, anti-ataxic mechanisms of action in the cerebellum and ongoing studies of the effect of these compounds in cachexic states.. A significant component of Prof. Whalley’s research has also been the development of experimental platforms which combine biological (e.g. neuronal cell culture, acute brain slices) and machine (e.g. robotic) systems to produce brain-machine interfaces (BMI) as tools for investigating the cellular correlates of complex CNS functions, including stem cell-based approaches. This research has thus far culminated in development of the first bioelectrically functional, 3D human neuronal network from stem cells, using biocompatible scaffolds; work featured in recent BBC science programming. This BMI research has formed part of presentations to the UK Cabinet Office and the US Senate, features in New Scientist, The Lancet, national broadsheets, national and international television and radio, an exhibit at the London Science Museum.. Both of the above research strands were chosen to act as two of the three Research Excellence Framework (REF) Impact Case Studies submitted by the Reading School of Pharmacy. Prof. Whalley has won ~£6M grant funding since taking up his first independent academic position in 2005 and his current grant funding supports a research group of 2 PDRAs and 9 PhD students. He has successfully supervised 13 PhD students to completion (100% success rate)..
Last chance to register for the Annual APS PHARMSCI 2014 conference
. . APS PHARMSCI 2014 CONFERENCE at the University of Hertfordshire de Havilland Campus, Hatfield from Monday 8th to Wednesday 10th September 2014.. With only a few days to go to this year’s APS PharmSci 2014 Conference, is proving one not to be missed by anyone working in the pharmaceutical science sector. With over 500 delegates registered and a programme of plenary lectures and sessions that will have something to appeal to all pharmaceutical scientists.. The speaker for the first Plenary Session is Dr Linda Hakes, who is this year’s APS PharmSci 2014 Scientific Chair and she will talk on the theme of the conference – ‘Working together, for patients'. Delegates will then have a choice of 42 parallel sessions over the 3 days, with over 100 speakers and chairs, talking on areas of pharmaceutical sciences that is both cutting edge science and shows how pharmaceutical scientists are experts in the research, development and manufacture medicines and have a major role in the regulation of medicines and understanding their use in patients. There will be many opportunities to network with the speakers for discussions and questions.. Speakers will talk over the three days, on subjects ranging from Nanotechnology in Pharma: Past, Present and Future; Future benefits and current analytical challenges; Oral dissolving dosage forms: Current opportunities; Microbiology; Age-related Medicines; Pharmacognosy - Drugs from Natural Sources; Biomaterials; Biopharmaceuticals; Process validation and continuous process verification; Medicinal Chemistry; Parenteral Drug Development: The Challenges of Adapting to Changing Patient Needs; Targeting skin and mucous membranes; Challenges with biotherapeutic development; Material Sciences; Skin delivery at the interface of industry and academia, and Inhaled: New Technologies and Novel Therapeutics. A roundtable session will introduce the concept of a drug product Manufacturing Classification System (MCS) based on processing route and seek feedback from the wider pharmaceutical science community on the best way to apply it to practice. The conference also has sessions for New Scientists which will include presentations from established and emerging scientists, and the Student Association of the APS will present a session on networking and the use of social media to succeed. . Several plenary sessions will be delivered over the 3 days by the winners of awards, 2014 Royal Pharmaceutical Society Science Award, APS Invited lecture, and GSK Emerging Scientist Award 2014.. A Science Café looking at the Investment in new antibiotics or the supply of fresh water - which will save more lives? , will prove a good way to start your conference on the second day.. There is also an opportunity for SMEs to show case their technologies at 2 dedicated sessions.. There will also be opportunities to view the 325 posters that have been submitted over the 3 days and talk with the authors.. For further networking opportunities and to enjoy the social side of the conference there are events organised each day, on the Monday evening, what will prove to be a lively debate, The role of universities in open innovation research: academic entrepreneurship or industrial exploitation?’ and on the Tuesday evening the APS annual “Black Tie Dinner" at Knebworth House.. For more information on these sessions. please see our news blog section here:. There is still time to register for the conference, for the full programme and registration see .
The role of universities in open innovation research: academic entrepreneurship or industrial exploitation- You have your say
“Open innovation” describes a new paradigm for the management of industrial innovation in the 21st century, in which universities can work with external partners to both commercialise their internal innovations and to obtain a source of external innovations that can be commercialized. The term was coined by Henry Chesbrough, based on his research on the innovation practices of large multinational companies.. What are your thoughts on this way of working? Would you like to be part of what will prove to be a lively debate jointly organised by the APS, University of Hertfordshire and Stevenage Bioscience Catalyst on Monday 8th September 7pm at the APS Pharm Sci 2014. ?. The debate will be led by Dr Darragh Murnane, Associate Dean Enterprise, University of Hertfordshire. The debating panel consists of three prominent speakers Professor Bill Dawson representing Stevenage Bioscience Catalyst, Professor Marc Brown of UH/MedPharm Ltd and Professor Adrian Davis of Limeway Consultancy who each will deliver a statement speech followed by the panel discussion. Then it will be your chance to get involved and ask questions of the panel.. The event is free with an optional cost of £10 for a buffet and will take place at the De Havilland Club, De Havilland Campus, University of Hertfordshire.. For more information please click on the following link
Follow us
Upcoming Events
MIBio 2014 - Stability of biopharmaceuticals- getting the chemistry right
30th September 2014
APS Board Meeting
14 - 15 October 2014
APS PharmSci 2015
7 - 9 September 2015
APS PharmSci 2016
5 - 7 September 2016
View all Vacancies
Advertise your job vacancies
Sponsored By
Join Us

Join the academy and get discounts on events, post-nominals, latest news and more.


The Academy of Pharmaceutical Sciences
Unit Q, Troon Way Business Centre
Humberstone Lane, Leicester, LE4 9HA
Tel: 0116 274 7351
Fax: 0116 274 7365

Terms of use:
The material included on this site is provided for information purposes only, and we make no representations or warranties as to its accuracy. Before relying on this material, you should take care to verify its accuracy, taking professional advice as appropriate.